76 related articles for article (PubMed ID: 35226982)
1. Cytofluorimetric assay to investigate variability in blinatumomab
Braidotti S; Franca R; Granzotto M; Piscianz E; Tommasini A; Rabusin M; Stocco G; Decorti G
Front Biosci (Landmark Ed); 2022 Jan; 27(2):39. PubMed ID: 35226982
[TBL] [Abstract][Full Text] [Related]
2. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.
Qi Y; Liu H; Li X; Shi Y; Mu J; Li J; Wang Y; Deng Q
Ann Med; 2023 Dec; 55(1):2230888. PubMed ID: 37417690
[TBL] [Abstract][Full Text] [Related]
3. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia.
Li Y; Moriyama T; Yoshimura S; Zhao X; Li Z; Yang X; Paietta E; Litzow MR; Konopleva M; Yu J; Inaba H; Ribeiro RC; Pui CH; Yang JJ
Sci Adv; 2022 Dec; 8(50):eadd6403. PubMed ID: 36516256
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia.
Shimazu Y; Kitawaki T; Kondo T; Takaori-Kondo A
Cancer Immunol Immunother; 2023 Nov; 72(11):3861-3865. PubMed ID: 37550429
[TBL] [Abstract][Full Text] [Related]
5. Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience.
Duminuco A; Markovic U; Parrinello NL; Lo Nigro L; Mauro E; Vetro C; Parisi M; Maugeri C; Fiumara PF; Milone G; Romano A; Di Raimondo F; Leotta S
Front Immunol; 2023; 14():1195734. PubMed ID: 37809082
[TBL] [Abstract][Full Text] [Related]
6. Blinatumomab in Practice.
Lantz J; Pham N; Jones C; Reed D; El Chaer F; Keng M
Curr Hematol Malig Rep; 2024 Feb; 19(1):1-8. PubMed ID: 38060085
[TBL] [Abstract][Full Text] [Related]
7. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.
Duell J; Dittrich M; Bedke T; Mueller T; Eisele F; Rosenwald A; Rasche L; Hartmann E; Dandekar T; Einsele H; Topp MS
Leukemia; 2017 Oct; 31(10):2181-2190. PubMed ID: 28119525
[TBL] [Abstract][Full Text] [Related]
8. Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
Ocadlikova D; Lussana F; Fracchiolla N; Bonifacio M; Santoro L; Delia M; Chiaretti S; Pasciolla C; Cignetti A; Forghieri F; Grimaldi F; Corradi G; Zannoni L; De Propris S; Borleri GM; Tanasi I; Vadakekolathu J; Rutella S; Guarini AR; Foà R; Curti A;
Br J Haematol; 2023 Nov; 203(4):637-650. PubMed ID: 37700538
[TBL] [Abstract][Full Text] [Related]
9. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Philipp N; Kazerani M; Nicholls A; Vick B; Wulf J; Straub T; Scheurer M; Muth A; Hänel G; Nixdorf D; Sponheimer M; Ohlmeyer M; Lacher SM; Brauchle B; Marcinek A; Rohrbacher L; Leutbecher A; Rejeski K; Weigert O; von Bergwelt-Baildon M; Theurich S; Kischel R; Jeremias I; Bücklein V; Subklewe M
Blood; 2022 Sep; 140(10):1104-1118. PubMed ID: 35878001
[TBL] [Abstract][Full Text] [Related]
10. Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy.
Franquiz MJ; Short NJ
Biologics; 2020; 14():23-34. PubMed ID: 32103893
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD19/CD8 bispecific T cell engager for the potential treatment of B cell malignancies.
Maghsoodi N; Zareinejad M; Golestan A; Mahmoudi Maymand E; Ramezani A
Cell Immunol; 2023; 393-394():104787. PubMed ID: 37976975
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic features of relapsed CD19(-) B-ALL in CD19-targeted immunotherapy: Biological insights into relapse and LILRB1 as a novel B-cell marker for CD19(-) B lymphoblasts.
Chen D; Fuda F; Rosado F; Saumell S; John S; Chen M; Koduru P; Chen W
Int J Lab Hematol; 2024 Jun; 46(3):503-509. PubMed ID: 38177979
[TBL] [Abstract][Full Text] [Related]
13. Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study.
Subklewe M; Magno G; Gebhardt C; Bücklein V; Szelinski F; Arévalo HJR; Hänel G; Dörner T; Zugmaier G; von Bergwelt-Baildon M; Skapenko A; Schulze-Koops H
Eur J Cancer; 2024 Jun; 204():114071. PubMed ID: 38691878
[TBL] [Abstract][Full Text] [Related]
14. Human plasma cells engineered to secrete bispecifics drive effective
Hill TF; Narvekar P; Asher G; Camp N; Thomas KR; Tasian SK; Rawlings DJ; James RG
bioRxiv; 2023 Aug; ():. PubMed ID: 37662410
[TBL] [Abstract][Full Text] [Related]
15. Direct long-read RNA sequencing identifies a subset of questionable exitrons likely arising from reverse transcription artifacts.
Schulz L; Torres-Diz M; Cortés-López M; Hayer KE; Asnani M; Tasian SK; Barash Y; Sotillo E; Zarnack K; König J; Thomas-Tikhonenko A
Genome Biol; 2021 Jun; 22(1):190. PubMed ID: 34183059
[TBL] [Abstract][Full Text] [Related]
16. T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.
Cech P; Skórka K; Dziki L; Giannopoulos K
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672662
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity.
Xu Y; Hijazi Y; Wolf A; Wu B; Sun YN; Zhu M
CPT Pharmacometrics Syst Pharmacol; 2015 Sep; 4(9):507-15. PubMed ID: 26451330
[TBL] [Abstract][Full Text] [Related]
18. CD19-negative B-cell precursors in bone marrow: A potential mimicker for CD19-negative B-lymphoblastic leukemia by flow cytometry in patients with anti-CD19 treatment.
Li W; Morgan R; Nieder R; Habeebu SSM; Myers GD
Cytometry B Clin Cytom; 2023 Sep; 104(5):392-396. PubMed ID: 37497861
[No Abstract] [Full Text] [Related]
19. pH controlled staining of CD4(+) and CD19(+) cells within functionalized microfluidic channel.
Mortato M; Blasi L; Barbarella G; Argentiere S; Gigli G
Biomicrofluidics; 2012; 6(4):44107. PubMed ID: 24191176
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
